DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST
EDGAR Filing Documents for 0001493152-21-001207
Blockchain-Fueled Company Mateon Develops Phase 3 Clinical Drug Candidate, Against COVID-19 - OT-101 – Blockchain News, Opinion, TV and Jobs
Windlas Biotech and Mateon Therapeutics launch first-ever Drug-Device Lung Therapy Combined AI 360 platform for respiratory wellness - The Statesman
A Covid-19 treatment plan slowly emerges | Evaluate
Mateon | HealthWire
MATEON THERAPEUTICS AKTIE | Aktienkurs | US6283411097 | News | A14Y0U | finanzen.net
FinData: Share Price for NASDAQ, MATN - Mateon Therapeutics Inc.
NantCell Binding Termsheet | MATEON THERAPEUTICS INC | Business Contracts | Justia
EX-4.1
Articles about Mateon Therapeutics, Inc.
Windlas Biotech, Mateon Therapeutics launch drug-device plus lung therapy platform - Express Pharma
Mateon Therapeutics - BIO Investor Forum | BIO
COVID Pandemic Hastens Search For New Technology And CRO Partner
Consulting Agreement by and between the Company and Artius, | MATEON THERAPEUTICS INC | Business Contracts | Justia
Combined CA4P (Fosbretabulin) therapy in Cancer- Ashini R. Dias, Contributor | Cancer Biology
Mateon and PointR to merge into AI-driven oncology firm
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
Mateon Therapeutics
Windlas Biotech, Mateon Therapeutics launch integrated solution for respiratory wellness in India
Mateon Therapeutics
MATEON'S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST
About Us – Oncotelic
Zacks Small-Cap Research
Mateon Therapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
Mateon Therapeutics completes acquisition of PointR Data
